BI1744염산염

개요Olodaterol hydrochloride was approved for long-term, oncedaily maintenance treatment of chronic obstructive pulmonary disease (COPD) in 2013 in the following countries: Canada, Russia, United Kingdom, Denmark, and Iceland. The drug has been recommended by a federal advisory panel for approval by the FDA. Developed and marketed by Boehringer Ingelheim, olodaterol is a long-acting b2-adrenergic receptor agonist with high selectivity over the b1- and b3-receptors (219- and 1622-fold, respectively). Upon binding to and activating the b2-adrenergic receptor in the airway, olodaterol stimulates adenyl cyclase to synthesize cAMP, leading to the relaxation of smooth muscle cells in the airway. Administered by inhalation using the Respimat® Soft Mist inhaler, it delivers significant bronchodilator effects within five minutes of the first dose and provides sustained improvement in forced expiratory volume (FEV1) for over 24 h.

용도Olodaterol is a long acting β-adrenoceptor agonist used as an inhalation for treating patients with chronic obstructive pulmonary disease (COPD).